Monopar Therapeutics Inc (MNPR)
R&D Expense Growth
36.69%
Quarterly · Period ending:
MNPR R&D Expense Growth
Latest reported36.69%period ending
Latest reported36.69%period ending
MNPR Quarterly R&D Growth (QoQ) (0.00% → 36.69%)
Latest values, visible window
High-resolution chart · PNG
MNPR r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 36.6933% | |
| -11.5159% | |
| 52.1808% | |
| 49.6965% | |
| 5.2712% | |
| -83.4414% | |
| 908.3147% | |
| -12.9711% | |
| 17.0651% | |
| -6.7093% | |
| -21.3388% | |
| -17.4447% | |
| -3.5477% | |
| -21.3793% | |
| 21.4024% | |
| -16.6584% | |
| 23.871% | |
| -15.3704% | |
| 8.5018% | |
| 23.7662% | |
| 22.3447% | |
| -26.0721% | |
| 29.9747% | |
| 50.8602% | |
| 141.7207% | |
| -41.0038% | |
| 165.5395% | |
| -33.2372% | |
| -60.5919% | |
| 60.3894% | |
| 71.554% | |
| -38.3567% | |
| 7.767% | |
| 47.7914% | |
| -97.8932% | |
| 4,611.9159% | |
| 132.9911% | |
| 37.4075% | |
| 40.6474% | |
| 21.5891% | |
| -0.0018% | |
| 0% |